Prelude Therapeutics

PRLD | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.70

-$0.17 (-3.49%)

At close: Sep 21, 2026, 4:00 PM ET

$4.85

+$0.15 (+3.19%)

Pre-market: Sep 22, 2026, 7:17 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-3.49%

(1D)

Rating

Updated: Aug 12, 2026

25.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $267.58M

1D Range

4.69 4.83

52W Range

0.99 6.83

Valuation (TTM)

PE -5.95

PB 2.00

EV/EBITDA -2.27

Valuation (NTM)

Forward PE 34.64

Forward PEG 0.24

Price Target $8

Cash Flow

FCF Yield -12.4%

SBC Adj. FCF Yield -15.5%

SBC Impact -24.9%

Margins

Gross Margin 98.3%

Operating Margin -300.6%

FCF Margin -148.3%

Growth (CAGR)

Revenue 3Y | 5Y 114.3% | 88.1%

Dil EPS 3Y | 5Y 36.1% | 22.2%

FCF 3Y | 5Y 44.2% | 12.4%

Returns

ROA -31.9%

ROE -75.3%

ROIC -43.7%

Financial Health

Net Cash

$134.11M

Current Ratio 4.07

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs....

Sector Healthcare

Industry Biotechnology

Employees 79

IPO Date Sep 24, 2020

Website www.preludetx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 11, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+70.21%

Buy (2)

Hold (0)

Sell (0)

Analyst Details ➞